9.97
0.01 (0.10%)
| Previous Close | 9.96 |
| Open | 10.07 |
| Volume | 135,142 |
| Avg. Volume (3M) | 1,279,909 |
| Market Cap | 1,604,920,832 |
| Price / Earnings (Forward) | 19.61 |
| Price / Sales | 4.60 |
| Price / Book | 1.64 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2024 |
| Profit Margin | -8.34% |
| Operating Margin (TTM) | 6.74% |
| Diluted EPS (TTM) | -0.200 |
| Quarterly Revenue Growth (YOY) | 10.80% |
| Total Debt/Equity (MRQ) | 29.53% |
| Current Ratio (MRQ) | 2.86 |
| Operating Cash Flow (TTM) | 54.42 M |
| Levered Free Cash Flow (TTM) | 70.56 M |
| Return on Assets (TTM) | 0.59% |
| Return on Equity (TTM) | -2.95% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Mixed | Bearish |
| Health Information Services (Global) | Mixed | Bearish | |
| Stock | Certara, Inc. | Bearish | Bearish |
Stockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.38 |
|
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Core |
| % Held by Insiders | 2.59% |
| % Held by Institutions | 92.08% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Teacher Retirement System Of Texas | 30 Sep 2024 | 4,000,603 |
| Brown Brothers Harriman & Co | 30 Sep 2024 | 2,330,615 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 16.00 (UBS, 60.48%) | Buy |
| Median | 13.00 (30.39%) | |
| Low | 12.00 (Barclays, 20.36%) | Hold |
| Average | 13.67 (37.11%) | |
| Total | 1 Buy, 2 Hold | |
| Avg. Price @ Call | 11.02 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 07 Nov 2024 | 12.00 (20.36%) | Hold | 10.99 |
| 15 Oct 2024 | 14.00 (40.42%) | Hold | 11.21 | |
| Baird | 05 Nov 2024 | 13.00 (30.39%) | Hold | 10.31 |
| UBS | 27 Sep 2024 | 16.00 (60.48%) | Buy | 11.75 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Nov 2024 | Announcement | Certara Reports Third Quarter 2024 Financial Results |
| 28 Oct 2024 | Announcement | Certara to Participate in the Stephens Annual Investment Conference |
| 16 Oct 2024 | Announcement | Certara Appoints John Reynders as New Independent Board Member |
| 09 Oct 2024 | Announcement | Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024 |
| 02 Oct 2024 | Announcement | Certara Completes Acquisition of Chemaxon |
| 02 Oct 2024 | Announcement | Certara Completes Acquisition of Chemaxon |
| 24 Sep 2024 | Announcement | Certara’s Simcyp Consortium Celebrates 25th Anniversary |
| 18 Sep 2024 | Announcement | Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug |
| 21 Aug 2024 | Announcement | Certara to Participate in Upcoming Investor Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |